Feuerstein's Biotech-Stock Mailbag: Panacos
This column originally posted on RealMoney.com at 6:59 a.m. EDT. For more information about subscribing to RealMoney, please click here.
The Biotech Mailbag is open. Our first email comes from Joe B., who asks for my thoughts on Panacos Pharmaceuticals (PANC).
Joe's email has been sitting in the mailbag for a long while, but it's timely this week because Panacos announced that company researchers have figured out a way to identify the sub-population of HIV patients who respond favorably to its experimental drug beviramat.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV